Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 trial of MK-7684 (vibostolimab) alone and with pembrolizumab in advanced solid tumors
jRCT2080224733Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1 trial of vibostolimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), gastric adenocarcinoma and 1 more (5 arms), sponsored by Merck & Co. Started Jun 2019; status: completed.
02
Drugs
vibostolimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080224733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224733.